Autoimmune hepatitis cholestatic variant syndromes recurrence following liver transplantation affects graft and patient survival in an international multicentre cohortDIGESTIVE AND LIVER DISEASEIF3.82024-02-010PRE
Histologic stage is a stronger predictor of transplant free survival than APRI and FIB-4 in patients with primary biliary cholangitisJOURNAL OF HEPATOLOGYIF332018-04-010PREAI
Primary biliary cholangitis (PBC) in the US: real world effectiveness of obeticholic acid in TARGET-PBCJOURNAL OF HEPATOLOGYIF332018-04-010PREAI
Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 studyJOURNAL OF HEPATOLOGYIF332018-04-014PREAI
Stratification of hepatocellular carcinoma risk using the GLOBE score in patients with primary biliary cholangitis-the Global PBC Study GroupJOURNAL OF HEPATOLOGYIF332018-04-010OAAI
Primary biliary cholangitis (PBC) in the US: clinical characteristics of patients enrolled in TARGET-PBCJOURNAL OF HEPATOLOGYIF332018-04-010PREAI
Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary CholangitisJOURNAL OF HEPATOLOGYIF332018-04-010PREAI
Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis - even in patients without biochemical improvementsJOURNAL OF HEPATOLOGYIF332018-04-014PREAI
A dose-response relationship in the association between ursodeoxycholic acid treatment and prolonged transplant-free survival in primary biliary cholangitisJOURNAL OF HEPATOLOGYIF332018-04-010OAAI
Increase in age at diagnosis of Primary Biliary Cholangitis over the last 40 yearsJOURNAL OF HEPATOLOGYIF332017-01-011PREAI
The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over timeJOURNAL OF HEPATOLOGYIF332017-01-013PREAI
Effect of obeticholic acid treatment in patients with primary biliary cholangitis on categorical shifts in GLOBE scoreJOURNAL OF HEPATOLOGYIF332017-01-010PREAI
MITIGATION OF PRURITUS DURING OBETICHOLIC ACID TREATMENT IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS: STRATEGIES AND SUCCESSESJOURNAL OF HEPATOLOGYIF332016-01-011PREAI
BEHAVIORAL PATTERNS OF TOTAL SERUM BILIRUBIN PRIOR TO MAJOR CLINICAL ENDPOINTS IN 3529 PATIENTS WITH PRIMARY BILIARY CHOLANGITISJOURNAL OF HEPATOLOGYIF332016-01-014PREAI
IDENTIFICATION OF PBC PATIENTS IN NEED OF ADDITIONAL THERAPY DURING THE COURSE OF UDCA TREATMENT AN INTERNATIONAL MULTICENTER STUDYJOURNAL OF HEPATOLOGYIF332015-04-011PREAI
PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF USTEKINUMAB IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS WHO HAD AN INADEQUATE RESPONSE TO URSODEOXYCHOLIC ACIDJOURNAL OF HEPATOLOGYIF332014-04-0111PREAI
EFFECTIVE STRATIFICATION OF HEPATOCELLULAR CARCINOMA RISK IN PRIMARY BILIARY CIRRHOSIS: RESULTS OF A MULTI-CENTRE INTERNATIONAL STUDYJOURNAL OF HEPATOLOGYIF332014-04-012PREAI
THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC)JOURNAL OF HEPATOLOGYIF332012-04-0110PREAI
LONG-TERM (LT) THERAPY OF A FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) MAINTAINS BIOCHEMICAL RESPONSE IN PRIMARY BILIARY CIRRHOSIS (PBC)JOURNAL OF HEPATOLOGYIF332012-04-013PREAI
FARNESOID-X RECEPTOR AGONISTS: A NEW CLASS OF FOR THE TREATMENT OF PBC? AN INTERNATIONAL STUDY EVALUATING THE ADDITION OF INT-747 TO URSODEOXYCHOLIC ACIDJOURNAL OF HEPATOLOGYIF332010-04-0147PRE
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向